Alto Neuroscience (ANRO) Stock Price, News & Analysis

Company Overview

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with psychiatric and neurological disorders. The company seeks to use neuroscience, digital health tools and biological and behavioral biomarkers to identify patient subgroups that may respond to specific treatments.

Alto’s pipeline has included investigational therapies for major depressive disorder and other central nervous system conditions. Its development programs are designed to address limitations of conventional psychiatric treatment by matching therapies to patient characteristics and measuring treatment response through objective data. The company’s drug candidates remain investigational and are subject to clinical and regulatory evaluation.

Founded by psychiatrist and neuroscientist Amit Etkin, Alto Neuroscience is headquartered in the United States and conducts its research and clinical development activities through collaborations and clinical studies primarily involving U.S. patients and institutions. The company is listed on the New York Stock Exchange under the symbol ANRO.

Key Stats

• Today's Range: $23.87 to $26.10
• 50-Day Range: $24.77 to $36.75
• 52-Week Range: $4.71 to $37.48
• Volume: 660,689 shs
• Average Volume: 598,154 shs
• Market Capitalization: $972.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $37.25
• Consensus Rating: Moderate Buy

Alto Neuroscience Stock Analysis - MarketRank™

Alto Neuroscience scored higher than 46% of companies evaluated by MarketBeat, and ranked 561st out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Alto Neuroscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on no strong buy ratings, 8 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Alto Neuroscience has a consensus price target of $37.25, representing about 50.4% upside from its current price of $24.77.

Amount of Analyst Coverage

Alto Neuroscience has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Alto Neuroscience are expected to decrease in the coming year, from ($2.68) to ($3.04) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alto Neuroscience is -10.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alto Neuroscience is -10.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Alto Neuroscience has a P/B Ratio of 5.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.99% of the float of Alto Neuroscience has been sold short.

Short Interest Ratio / Days to Cover

Alto Neuroscience has a short interest ratio ("days to cover") of 9.08.

Change versus previous month

Short interest in Alto Neuroscience has recently increased by 8.80%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alto Neuroscience does not currently pay a dividend.

Dividend Growth

Alto Neuroscience does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.29

News Sentiment

Alto Neuroscience has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Alto Neuroscience this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for ANRO on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Alto Neuroscience to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Alto Neuroscience insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,566,987.00 in company stock.

Percentage Held by Insiders

11.25% of the stock of Alto Neuroscience is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Alto Neuroscience has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/03/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:ANRO
• Previous Symbol: NYSE:ANRO
• CIK: 1999480
• Web: www.altoneuroscience.com
• Phone: (773) 255-5012
• Fax: N/A
• Employees: 68
• Year Founded: 2019

Price Target and Rating

• Average Price Target for Alto Neuroscience: $37.25
• High Price Target: $55.00
• Low Price Target: $26.00
• Potential Upside/Downside: +50.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.64
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.42)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$63.24 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -46.46%
• Return on Assets: -39.09%

Debt

• Debt-to-Equity Ratio: 0.07
• Current Ratio: 14.85
• Quick Ratio: 14.85

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.87 per share
• Price / Book: 5.09

Miscellaneous

• Outstanding Shares: 39,242,000
• Free Float: 34,827,000
• Market Cap: $972.10 million
• Optionable: N/A
• Beta: 1.32